Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Sinaptica Therapeutics™

Noninvasive Neuromodulation: A True Breakthrough in Alzheimer's Disease

## Sitemaps

- [XML Sitemap](https://sinapticatx.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Sinaptica releases “Living Through the Longest Goodbye" mini-documentary](https://sinapticatx.com/sinaptica-releases-living-through-the-longest-goodbye-mini-documentary/) - Sinaptica spoke with people most impacted by Alzheimer’s disease and produced this powerful short film to shine a spotlight on the impact of the disease. Through the emotional voices of caregivers, clinicians, and those living closest to this devastating disease, this film captures what statistics cannot: what Alzheimer’s feels like inside a family, what it
- [Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy](https://sinapticatx.com/sinaptica-therapeutics-completes-scientific-advisory-board-bringing-together-leading-voices-across-patients-science-medicine-and-commercial-strategy/) - Cambridge, MA – December 22, 2025 – Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced the completion of its Scientific Advisory Board (SAB), bringing together a uniquely comprehensive group of experts spanning neuroscience, clinical development, brain health,
- [Sinaptica Therapeutics Receives Funding from The Centre for Aging + Brain Health Innovation and Baycrest to Advance Breakthrough Neuromodulation Therapy for Alzheimer’s](https://sinapticatx.com/sinaptica-therapeutics-receives-funding-from-the-centre-for-aging-brain-health-innovation-and-baycrest-to-advance-breakthrough-neuromodulation-therapy-for-alzheimers/) - Cambridge, MA – December 11, 2025 – Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, has received funding from The Centre for Aging + Brain Health Innovation (CABHI), in partnership with Baycrest, one of North America’s leading academic
- [Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity in Key Brain Network in Alzheimer’s Patients](https://sinapticatx.com/alzheimers-research-and-therapy/) - Study by Sinaptica scientific co-founders published in Alzheimer's Research & Therapy Imaging analysis revealed personalized rTMS-EEG preserved structural integrity, enhanced functional connectivity, and slowed atrophy in areas of the Default Mode Network, the primary memory network impacted by Alzheimer’s that is targeted by the therapy Findings support the company’s Phase 2 data in Mild/Moderate Alzheimer’s
- [FDA breakthrough device designation stimulates increased interest](https://sinapticatx.com/fda-breakthrough-device-designation-stimulates-increased-interest/) - Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough device designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, brain wave monitoring, and artificial intelligence (AI) to address the cognitive and functional decline in patients with neurological disorders. “We are excited that the FDA has recognized the groundbreaking potential of our SinaptiStim–AD System with
- [Sinaptica FDA Breakthrough Device Designation](https://sinapticatx.com/sinaptica-fda-breakthrough-device-designation/) - Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease patients Breakthrough designation is based on positive outcomes from a Phase II clinical trial in mild-to- moderate Alzheimer’s disease
- [Publication in Alzheimer’s & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for Alzheimer’s](https://sinapticatx.com/publication-in-alzheimers-dementia-elucidates-multimodal-mechanism-of-action-underpinning-promising-new-neuromodulation-therapy-for-alzheimers/) - Review publication details benefits of repetitive transcranial magnetic stimulation (rTMS) on Alzheimer’s, including increases in neuroplasticity and other structural and functional second order impacts on the brainSeminal publication on rTMS in Alzheimer’s authored by Sinaptica scientific co-founders along with other experts in neuromodulation and Alzheimer’s diseaseCambridge, MA – June 18, 2025 – Sinaptica Therapeutics, Inc., a
- [Small mid-stage trial suggests targeted magnetic pulses to brain could slow Alzheimer’s](https://sinapticatx.com/small-mid-stage-trial-suggests-targeted-magnetic-pulses-to-brain-could-slow-alzheimers/) - BY JONATHAN WOSENPatients receiving transcranial magnetic stimulation had slower disease progressionREAD THE FULL ARTICLE
- [How Personalized Repetitive Transcranial Magnetic Stimulation May Transform Alzheimer Treatment](https://sinapticatx.com/how-personalized-repetitive-transcranial-magnetic-stimulation-may-transform-alzheimer-treatment/) - BY MARCO MEGLIO READ THE FULL ARTICLE The Alzheimer disease (AD) treatment pipeline is ever evolving, with numerous different modalities and targets currently being explored. In recent years, the field has had major breakthroughs with the development and commercialization of monoclonal antibodies targeting amyloid plaques; however, several in the field believe that these therapeutics will
- [Positive Data Published in Alzheimer’s Research & Therapy from 12-month Phase 2 Study in Alzheimer’s Using Personalized Neuromodulation Therapy; Trial Met All Primary and Key Secondary Endpoints](https://sinapticatx.com/positive-data-published-in-alzheimers-research-trial-met-all-primary-and-key-secondary/) - Data showed strong separation from placebo and statistical significance in mild-to-moderate patients on key measures including CDR-SB, ADAS-Cog11, ADCS-ADL, and NPIPersonalized Neuromodulation (nDMN) targeting the Default Mode Network slowed Alzheimer’s in all 3 clinically measured domains: cognition, function, and behavior—with no serious side-effectsThis positive peer reviewed 52-week study builds upon prior positive clinical studies and provides
- [Early neurotechnology trials have seen some success. Here are the details.](https://sinapticatx.com/early-neurotechnology-trials-have-seen-some-success-here-are-the-details/) - BY CHARLOTTE HUHow different brain stimulation devices are being tested as an alternative to the standard of care. Neuromodulation technology, also known as neurotechnology, is making a return as a form of treatment for a range of medical conditions. Most recently, it’s appeared in clinical trials for Alzheimer’s, depression, and chronic pain therapies. Here’s a
- [Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System](https://sinapticatx.com/enrollment-initiated-for-phase-2-clinical-trial-in-early-alzheimers-with-sinapticas-second-generation-precision-neuromodulation-system/) - Proprietary approach combines two neurostimulation modalities simultaneously, with the potential to enhance efficacy while reducing treatment time by 70%Recently published Phase 1 data in healthy volunteers demonstrated significant improvement in memory, establishing the potential for this novel approach in Alzheimer’s patientsSinaptica’s patent pending technology creates the potential for a seamless future upgrade of the SinaptiStim®
- [Targeted Magnetic Stimulation Slows Alzheimer's Progression in Phase II Study](https://sinapticatx.com/targeted-magnetic-stimulation-slows-alzheimers-progression-in-phase-ii-study/) - BY GREG LAUBA personalized transcranial magnetic stimulation (TMS) protocol, designed to stimulate the precuneus within the default mode network, was well tolerated and significantly slowed clinical decline in patients with mild-to-moderate Alzheimer's disease, according to data from a small phase II trialopens in a new tab or window presented at the Clinical Trials on Alzheimer's
- [Sinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025](https://sinapticatx.com/sinaptica-announces-initiation-of-co-development-of-the-sinaptistim-precision-neuromodulation-system-to-treat-alzheimers-disease-on-track-for-pivotal-clinical-trial-initiation-in-2025/) - Development is underway for March delivery of the first non-invasive investigational neuromodulation system in coordination with partners Nexstim and BittiumBuilding on the recently released positive one-year Phase 2 clinical data in Alzheimer’s patients, the FDA-designated Breakthrough Device integrates TMS with EEG, adding a customized workflow and Sinaptica’s patented MAINTAIN™ cloud-based Personalization Software, which determines optimal
- [Are we entering a neurotechnology renaissance in healthcare?](https://sinapticatx.com/are-we-entering-a-neurotechnology-renaissance-in-healthcare/) - BY CHARLOTTE HUFor Alzheimer’s, chronic pain, and depression, brain stimulation may help where drugs fail.A seemingly old-school tech for treating neurological disorders is gearing up for a comeback. A class of neurotechnology known as neuromodulation is showing promising clinical results for patients with certain illnesses.Neuromodulation technology uses nervous system and brain stimulation devices to treat
- [Alzheimer's researchers say brain stimulation device may slow symptoms](https://sinapticatx.com/alzheimers-researchers-say-brain-stimulation-device-may-slow-symptoms/) - BY LINDA CARROLL AND MUSTAFA FATTAHIn a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain network that stores memories and is typically hard hit by the disease.READ THE FULL ARTICLE
- [Personalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints](https://sinapticatx.com/personalized-neuromodulation-treatment-significantly-slowed-alzheimers-progression-in-12-month-phase-2-study-meeting-primary-and-key-secondary-endpoints/) - Data presented at CTAD showed strong separation from placebo and statistical significance in mild-to-moderate patients on key global, cognitive, and behavioral measures including CDR-SB, ADAS- Cog11 and NPI. On key functional measure, Activities of Daily Living (ADCS-ADL), Alzheimer’s disease patients receiving treatment were nearly unchanged after one year. Personalized Neuromodulation (rTMS-EEG) targeting the Default Mode
- [TMS-EEG perturbation biomarkers for Alzheimer’s disease patients classification](https://sinapticatx.com/tms-eeg-perturbation-biomarkers-for-alzheimers-disease-patients-classification/) - The combination of TMS and EEG has the potential to capture relevant features of Alzheimer’s disease (AD) pathophysiology. We used a machine learning framework to explore time-domain features characterizing AD patients compared to age-matched healthy controls (HC). More than 150 time-domain features including some related to local and distributed evoked activity were extracted from TMS-EEG
- [Alzheimer’s Disease: Can Machine Learning Fix a Broken Brain Network?](https://sinapticatx.com/alzheimers-disease-can-machine-learning-fix-a-broken-brain-network/) - Sinaptica began its commercial journey only recently, although its deep scientific underpinnings have already gotten it through a positive Phase II trial, which dramatically showed the benefit of a noninvasive neuromodulation therapy designed to achieve a network effect that slows disease progression in patients with mild to moderate Alzheimer’s. The pathophysiology of Alzheimer’s disease is
- [Sinaptica Therapeutics: MedTech Upstart Takes on Alzheimer’s with Radical New Approach](https://sinapticatx.com/sinaptica-therapeutics-medtech-upstart-takes-on-alzheimers-with-radical-new-approach/) - Precision Neuromodulation of the Default Mode Network slows disease progression by an unprecedented 80%+ in landmark Phase 2 clinical study.Researchers have spent decades and billions trying to develop an effective treatment for Alzheimer’s disease, the most feared disease, ahead of cancer, stroke, and heart disease combined—according to a survey by the Milken Institute. Pharmaceutical approaches
- [It’s not just about plaques: rTMS also reduces cognitive and functional decline in Alzheimer’s](https://sinapticatx.com/its-not-just-about-plaques-rtms-also-reducescognitive-and-functional-decline-in-alzheimers/) - The growing number of drugs gaining U.S. FDA approval for Alzheimer’s disease has kept their ability to reduce amyloid beta and tau proteins in the news, but the degenerative disease is not simply a matter of tangles and deposits. A loss of synaptic plasticity and disrupted neural networks underlie the signature impairment of memory and
- [Noninvasive Brain Stimulation Shows Potential](https://sinapticatx.com/noninvasive-brain-stimulation-shows-potential/) - Noninvasive Brain Stimulation Shows Potential to Slow Cognitive and Functional Decline in Mild-to-Moderate Alzheimer Disease Patients treated with PC-rTMS showed almost no decline in the CDR-SB score, and presented a clear advantage in terms of cognitive functions in contrast to the worsening of the score observed in the sham group. Findings from a 24-week phase
- [Repetitive TMS to the Precuneus Stabilizes Cognitive Status](https://sinapticatx.com/repetitive-tms-to-the-precuneus-stabilizes-cognitive-status/) - This scientific commentary refers to ‘Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial’ by Koch et al. (https://doi.org/10.1093/brain/awac285). Neurodegenerative dementia, in particular Alzheimer’s disease, is a global crisis with no existing cure. Technologies targeting neuroplasticity of the brain offer hope for slowing disease progression, avoiding further decline, and even reversing the decline that
- [Shaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash](https://sinapticatx.com/shaping-the-future-of-alzheimers-care-interview-with-sinaptica-ceo-ken-mariash/) - Researchers have been looking for a cure for Alzheimer's disease for decades, with little success. Traditionally, the arsenal we’ve been using is largely reliant upon drugs. But could a device, not a pharmaceutical, be the key to Alzheimer's treatment? This is a possibility that Ken Mariash and his team are solving for at Sinaptica. Ken
- [Alzheimer’s: Approaching a Cure](https://sinapticatx.com/alzheimers-approaching-a-cure/) - This Phase 2 trial showed 80 percent+ slowing of Alzheimer's progression on gold standard cognitive and functional endpoints using non-invasive neuromodulation, leading to Sinaptica's founding. I've never encountered placebo–controlled efficacy data as strong.KEN MARIASH | CEO, SINAPTICA Prevalence and Economic ImpactAlzheimer's slow impairment of memory and cognitive functions continues to divide the wider scientific community,
- [Sinaptica’s Breakthrough Device Could Slow Brain Atrophy In Alzheimer’s Patients – Study](https://sinapticatx.com/sinapticas-breakthrough-device-could-slow-brain-atrophy-in-alzheimers-patients-study/) - Precision Neuromodulation of the Default Mode Network slows disease progression by an unprecedented 80%+ in landmark Phase 2 clinical study.Researchers have spent decades and billions trying to develop an effective treatment for Alzheimer’s disease, the most feared disease, ahead of cancer, stroke, and heart disease combined—according to a survey by the Milken Institute. Pharmaceutical approaches
- [Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’](https://sinapticatx.com/sinaptica-on-precision-neuromodulation-to-combat-alzheimers-no-drug-dares-go-after-moderate-patients/) - VIEW FULL ARTICLE HERE Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’by Ryan Nelson CEO Ken Mariash and scientific co-founder Giacomo Koch discuss plans for a Phase 3 trial in 2025 supporting Sinaptica’s combination of transcranial magnetic stimulation, electroencephalography and machine learning to slow Alzheimer’s progression. Potential synergies with
- [StartUp Health - Sinaptica Therapeutics: Bridging Neuroscience Gaps to Slow the Progression of Alzheimer's Disease](https://sinapticatx.com/startup-health-tvsinaptica-therapeutics-bridging-neuroscience-gaps-to-slow-the-progression-of-alzheimers-disease/)
- [Noninvasive brain stimulation slows Alzheimer's disease in yearlong trial](https://sinapticatx.com/noninvasive-brain-stimulation-slows-alzheimers-disease-in-yearlong-trial/) - BY DARREN INCORVAIAREAD THE FULL ARTICLEAs the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a different, noninvasive approach to treating Alzheimer’s disease.In a yearlong phase 2 study, Sinaptica Therapeutics’ personalized, precision transcranial magnetic brain stimulation slowed the progression of cognitive decline in patients with mild to
- [Personalized Noninvasive Neuromodulation Slows AD Progression](https://sinapticatx.com/personalized-noninvasive-neuromodulation-slows-ad-progression/) - BY MEGAN BROOKSNew research supports the therapeutic potential of repetitive transcranial magnetic stimulation (rTMS) for Alzheimer’s disease (AD).In a 52-week phase 2 trial, personalized rTMS applied over the precuneus, a core component of the default mode network (DMN), slowed the progression of cognitive and functional decline in patients with mild to moderate AD.As reported previously
- [Positive Phase II Alzheimer's trial results Published](https://sinapticatx.com/positive-phase-ii-alzheimers-trialresults-published/) - Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease Phase II sham-controlled randomized trial met its primary endpoint with statistical significance; treatment slowed cognitive decline by 82% over 6 months in the treated population compared to sham with no safety issues
- [Sinaptica Appoints Ken Mariash CEO](https://sinapticatx.com/sinaptica-appoints-ken-mariash-ceo/) - Company accelerates after unprecedented positive Phase 2 data in Alzheimer’s, showing >80% disease slowing on cognitive & functional endpoints CAMBRIDGE, Mass.-- Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer.
- [Sinaptica Completes Scientific Advisory Board with Final Expert Appointment as Company Advances to Pivotal Trial in Alzheimer's](https://sinapticatx.com/sinaptica-completes-scientific-advisory-board-with-final-expert-appointment-as-company-advances-to-pivotal-trial-in-alzheimer/) - Giovanni Frisoni, MD joins SAB comprised of prominent global Alzheimer’s, neuromodulation and neuroscience experts including Jeffrey Cummings MD, ScD(HC); Ana Pereira MD; Simone Rossi MD, PhD; Casey Lynch, MS SAB will help guide the company’s Phase 3 clinical development plans based on unprecedented Phase 2 data in Alzheimer’s showing >80% disease slowing on cognitive &
- [Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot](https://sinapticatx.com/sinaptica-therapeutics-selected-for-startup-healths-alzheimers-moonshot/) - Moonshot supported by Gates Ventures and Alzheimer’s Drug Discovery Foundation (ADDF)to accelerate innovation around Alzheimer’s Sinaptica is one of 14 companies initially selected that are advancing innovative solutions for Alzheimer’s to commercialization and scalability Collaboration will support the company’s Phase 3 clinical development plans based on unprecedented Phase 2 data in Alzheimer’s showing >80% disease
- [Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration with Sinaptica Therapeutics, Inc.](https://sinapticatx.com/insider-information-nexstim-plc-announces-planned-alzheimers-collaboration-with-sinaptica-therapeutics-inc/) - Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has successfully negotiated and signed a Letter of Intent (LOI) to exclusively collaborate with Sinaptica Therapeutics, Inc. (“Sinaptica”) to develop, manufacture and supply Sinaptica’s patented precision neuromodulation system custom-based upon the Nexstim NBS 6 system with its advanced TMS-EEG and precision neuronavigation capabilities, in the field
- [Sinaptica Therapeutics to Present Results of 52-week Phase 2 Study of Precision Neuromodulation for Alzheimer’s Diseases in Oral Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) Conference](https://sinapticatx.com/sinaptica-therapeutics-to-present-results-of-52-week-phase-2-study-of-precision-neuromodulation-for-alzheimers-diseases-in-oral-presentation-at-clinical-trials-on-alzheimers-disease/) - Cambridge, MA – October 31, 2024 – Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced that the company will present an oral presentation with results of a 52-week Phase 2 study in Mild-to-Moderate Alzheimer’s disease at
- [Sinaptica featured on Mass Device](https://sinapticatx.com/sinaptica-featured-on-mass-device/) - Sinaptica's neurostim treatment for Alzheimer's wins FDA Breakthrough nod Sinaptica Therapeutics announced today that it received FDA breakthrough device designation for its investigational SinaptiStim AD system. Cambridge, Massachusetts-based Sinaptica designed its system to treat cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD). The system creates a novel integration of neurostimulation and brain

## Pages

- [Home](https://sinapticatx.com/) - Sinaptica Therapeutics™ has developed a breakthrough personalized closed-loop neuromodulation therapy for Alzheimer’s Disease that works by enhancing neuroplasticity via neurostimulation of key brain networks involved in memory.
- [](https://sinapticatx.com/mission/living-through-the-longest-goodbye/) - Watch our short documentary: “Living Through the Longest Goodbye" Through the emotional voices of caregivers, clinicians, and those living closest to this devastating disease, this film captures what statistics cannot: what Alzheimer’s feels like inside a family, what it asks of the people who love someone through it, and why the search for new treatment
- [SCIENCE](https://sinapticatx.com/science/) - A BOLD NEW APPROACH What if Alzheimer's is as much an electrical disorder as it is biochemical? What if Alzheimer's is as much an electrical disorder as it is biochemical Given so many drug failures over 20 years, new approaches are needed. Even the latest amyloid drugs only slow the disease marginally, and with burdensome side-effects. Our mechanistic understanding
- [PUBLICATIONS](https://sinapticatx.com/publications/) - Publications Publications SINAPTICA FOUNDATIONAL PUBLICATIONS “The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer’s disease” Antonioni A, Martorana A, Santarnecchi E, Hampel H, Koch G, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, June 2025. “Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial” Koch G, Casula
- [News](https://sinapticatx.com/news/) - ARTICLES AND PRESS RELEASES Sinaptica In the News FEATURED NEWS June 18, 2025 Publication in Alzheimer’s & Dementia Elucidates Multimodal Mechanism of Action Underpinning Promising New Neuromodulation Therapy for Alzheimer’s CONTINUE READING April 2, 2025 Positive Data Published in Alzheimer’s Research & Therapy from 12-month Phase 2 Study in Alzheimer’s Using Personalized Neuromodulation Therapy; Trial
- [MEET THE TEAM](https://sinapticatx.com/meet-the-team/) - MEET THE TEAM Highly Experienced Scientific and Management Team Highly Experienced Scientific and Management Team Scientific co-founders are leading experts in noninvasive brain modulation andAlzheimer’s, and have been funded by leading institutions such as the ADDF, DARPA,NIH, and NASA. Scientific co-founders are leading experts in noninvasive brain modulation and Alzheimer’s, and have been funded by
- [Follow us](https://sinapticatx.com/follow-us/) - FOLLOW US Sign Up for Email Updates This form is intended for US residents only. I am a: PATIENT MEDICAL PROFESSIONAL CAREGIVER OTHER
- [demo video playlist](https://sinapticatx.com/demo-video-playlist/) - Playlist 3 Videos Personalized neuromodulation for Alzheimer's — the brain reveals its bioelectric secrets 2:27 Personalization: Developing a Personalized Neuromodulation Therapy for Alzheimer's 3:01 Clinical Trial with Personalized Neuromodulation of the Default Mode Network for Alzheimer's 2:16
- [Jeffrey Cummings](https://sinapticatx.com/jeffrey-cummings/) - Jeffrey Cummings, MD ScD Scientific Advisor Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a
- [BOARD OF DIRECTORS](https://sinapticatx.com/board-of-directors/) - MEET THE TEAM Board of Directors Board of Directors Ken Mariash CEO Medtech & Biopharma Marketing, Strategy, & Corp Dev Executive. Former Head of Strategy, Boston Scientific Neuromodulation. Former Global Franchise GM, Cosman Medical. READ MORE Ken Mariash CEO Medtech & Biopharma Marketing, Strategy, & Corp Dev Executive. Former Head of Strategy, Boston Scientific Neuromodulation.
- [Mission](https://sinapticatx.com/mission/) - OUR MISSION Alzheimer’s: The Most Feared Disease in America Alzheimer’s: The Most Feared Disease in America Without new breakthrough approaches, millions of our seniors will have their minds– and their lives—slowly stolen from them. This is the Disease of the Century. Without new breakthrough approaches, millions of our seniors will have their minds and their
- [](https://sinapticatx.com/terms-of-service/) - Terms of Service Last Updated: November 2, 2022 Welcome, and thank you for your interest in Sinaptica Therapeutics, Inc. (“Sinaptica,” “we,” or “us”) and our website at sinapticatx.com, including subdomains of that website (collectively, the “Site”). These Terms of Use are a legally binding contract between you and Sinaptica regarding your use of the Site. PLEASE
- [](https://sinapticatx.com/privacy-policy-2/) - Privacy Policy Last Updated: November 2, 2022Sinaptica Therapeutics, Inc. (“Sinaptica,” “we,” “our,” and/or “us”) values the privacy of individuals who use our websites, and related services (collectively, our “Services”). This privacy policy (the “Privacy Policy”) explains how we collect, use, and share information from users of our Services (“Users”). By using our Services, you agree to
- [Sample Page](https://sinapticatx.com/sample-page/) - This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger

## Featured Publications

- [The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer’s disease](https://sinapticatx.com/featured-publication/the-neurobiological-foundation-of-effective-repetitive-transcranial-magnetic-brain-stimulation-in-alzheimers-disease/) - “The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer’s disease” Antonioni A, Martorana A, Santarnecchi E, Hampel H, Koch G, Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, June 2025.
- [Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized triala](https://sinapticatx.com/featured-publication/effects-of-52-weeks-of-precuneus-rtms-in-alzheimers-disease-patients-a-randomized-triala/) - “Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial” Koch G, Casula EP, Bonnì S, et al., Alzheimer’s Research & Therapy, April 2025.
- [Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study](https://sinapticatx.com/featured-publication/macro-and-micro-structural-preservation-of-grey-matter-integrity-after-24-weeks-of-rtms-in-alzheimers-disease-patients-a-pilot-study/) - “Macro and micro structural preservation of grey matter integrity after 24 weeks of rTMS in Alzheimer’s disease patients: a pilot study” Mencarelli L, Torso M, Borghi I, et al., Alzheimer’s Research & Therapy, April 2024.
- [Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial](https://sinapticatx.com/featured-publication/precuneus-magnetic-stimulation-for-alzheimers-disease-a-randomized-sham-controlled-trial/) - “Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial” Giacomo Koch, Elias Paolo Casula, Sonia Bonnì, Ilaria Borghi, Martina Assogna, Marilena Minei, Maria Concetta Pellicciari, Caterina Motta, Alessia D’Acunto, Francesco Porrazzini, Michele Maiella, Clarissa Ferrari, Carlo Caltagirone, Emiliano Santarnecchi, Marco Bozzali, Alessandro Martorana, Brain, November 2022. Commentary: “Repetitive TMS applied to the precuneus stabilizes cognitive

## Team

- [Anthony Arnold](https://sinapticatx.com/team/anthony-arnold/) - President/CEO of Sensydia Corporation. Previous President & Chief Executive Officer SetPoint Medical. Previous Vice President of Marketing for Boston Scientific.
- [Emiliano Santarnecchi PhD, PhD](https://sinapticatx.com/team/emiliano-santarnecchi-phd-phd/) - Associate Professor of Neurology & Radiology, Harvard Medical School. Director, Precision Neuroscience and Neuromodulation Program at Massachusetts General Hospital.
- [Giacomo Koch MD, PhD](https://sinapticatx.com/team/giacomo-koch-md-phd/) - Professor of Physiology, University of Ferrara. Director, Brain Stimulation Laboratory, Santa Lucia Foundation.
- [Yohannes Iyassu](https://sinapticatx.com/team/yohannes-iyassu/) - Software and ML Consultant. Former Vice President R&D Micro-Leads, Inc & Executive Director R&D, Nuvectra.
- [Greg Harper](https://sinapticatx.com/team/greg-harper/) - Ex-VP R&D Neuronetics. Ex-VP R&D Philips. Global functional manager and PMO leader in aerospace, medical imaging, and TMS.
- [Lisa Fosdick](https://sinapticatx.com/team/lisa-fosdick/) - VP Clinical Operations, Functional Neuromodulation (FNMI Deep Brain Stimulation of the Fornix for AD). Former Director, Data Management & BioStats, CVRx.
- [Ken Mariash](https://sinapticatx.com/team/ken-mariash/) - Medtech & Biopharma Marketing, Strategy, & Corp Dev Executive. Former Head of Strategy, Boston Scientific Neuromodulation. Former Global Franchise GM, Cosman Medical.
- [Rich Macary](https://sinapticatx.com/team/rich-macary/) - Healthcare Executive - Biotech & Med Device. Ex-VP of BD, Sarepta. Chief Strategy Officer, Delos. President, Delos Ventures. Managing Partner, Macary Advisors Inc.
- [Mark Wang](https://sinapticatx.com/team/mark-wang/) - Partner at Pureland Global Venture. Executive Program in Strategy for Healthcare Delivery at Harvard Business School.
- [Harald Hampel MD, PhD, MSc](https://sinapticatx.com/team/harald-hampel/) - Chief Medical Officer, Senior Vice President, Neurology, Eisai Inc.
- [Jim Schwoebel](https://sinapticatx.com/team/jim-schwoebel/) - Digital Health Executive at Verily (Google). Ex-VP Sonde Health (PureTech). Ex-CEO of NeuroLex DigitalOcean.
- [Alessio Travaglia](https://sinapticatx.com/team/alessio-travaglia/) - Dir, Neuroscience F-NIH. Former Director, ADDF. Former CEO and Founder of S2I LLC.
- [Simone Rossi, MD, PhD](https://sinapticatx.com/team/simone-rossi/) - Professor of Neurology, University of Siena. Director of the Siena Brain Investigation & Neuromodulation Lab (Si-BIN Lab) and of the Movement Disorders clinical section. Writer of popular science books on the brain and artificial intelligence.
- [Jim Taylor](https://sinapticatx.com/team/jim-taylor/) - President and CEO of Voices of Alzheimers and Memory Advocate Peers. FDA appointed Alzheimer’s patient advocate. Perennial Hero Award for their Alzheimer’s advocacy by the Alliance for Aging Research (DC). Successful career in IBM finance.
- [Henry Peck](https://sinapticatx.com/team/720/) - VP Growth & Strategy, LSI. Early Team & Former Director, Strategy & Marketing at Altoida. Former Clinical Engineer, Johnson & Johnson (Auris Health).
- [Chris Thatcher](https://sinapticatx.com/team/chris-thatcher/) - Former CEO Neuronetics. Senior Executive at Integra Life Sciences, Bausch & Lomb. Board Member - Micro Interventional Devices.
- [Jeffrey Cummings, MD, ScD (HC)](https://sinapticatx.com/team/jeffrey-cummings-md-scd/) - Research Professor at UNLV School of Integrated Health Sciences. Founding Director of the Cleveland Clinic Lou Ruvo Center for Brain Health.
- [Casey Lynch, MS](https://sinapticatx.com/team/casey-lynch/) - CEO/Founder Lighthouse Pharma. Business Review Board ADDF . BOD Longboard Pharma. Former CEO/Founder Cortexyme. Managing Partner/Founder NeuroInsights.
- [Ana Pereira, MD](https://sinapticatx.com/team/ana-pereira-md/) - Assoc Professor, Neurology and Neuroscience, Icahn School of Medicine, Mount Sinai. Clinical Practice, Mt Sinai. Director, Pereira Lab, Mt Sinai.
- [Giovanni Frisoni, MD](https://sinapticatx.com/team/giovanni-frisoni/) - Clinical neurologist, Full Professor of Clinical Neuroscience at the University of Geneva, Switzerland. Director of the Memory Clinic of the Geneva University Hospital. Former Scientific Director at the National Alzheimer’s Centre in Brescia, Italy. Fellow of the European Academy of Neurology.
- [Lorenzo Di Gioacchino](https://sinapticatx.com/team/lorenzo-di-gioacchino/) - Partner, F2i. Lawyer.
- [Dinesh Moorjani](https://sinapticatx.com/team/dinesh-moorjani/) - Founding Partner, Time Zero Capital. Cofounder, Tinder. Board Trustee, UC Merced. PhD Student Researcher, Urban Informatics Lab, Stanford University.

## Forms

- [Other Form](https://sinapticatx.com/metform-form/other-form/)
- [Patients form](https://sinapticatx.com/metform-form/patients-form/)
- [Medical Professional form](https://sinapticatx.com/metform-form/medical-professional-form/)
- [Caregiver form](https://sinapticatx.com/metform-form/caregiver-form/)

## Categories

- [Uncategorized](https://sinapticatx.com/category/uncategorized/)
- [Management Team](https://sinapticatx.com/category/management-team/)
- [Co-Founders](https://sinapticatx.com/category/co-founders/)
- [Board of Directors](https://sinapticatx.com/category/board-of-directors/)
- [Scientific Advisory Board](https://sinapticatx.com/category/scientific-advisory-board/)
- [Strategic Advisors](https://sinapticatx.com/category/strategic-advisors/)
- [Media Articles](https://sinapticatx.com/category/media-articles/)
- [Scientific Publications](https://sinapticatx.com/category/scientific-publications/)
- [Press Releases](https://sinapticatx.com/category/press-releases/)
- [Featured](https://sinapticatx.com/category/featured/)